Key result
Transgenic mice with hypertrophic cardiomyopathy demonstrated prolonged P-wave duration and PR intervals (P<0.001) and depressed heart rate variability compared to controls.
Why the study?
Does the Gly203Ser cardiac troponin-I mutation alter atrial/atrioventricular conduction and heart rate variability in a murine model of hypertrophic cardiomyopathy?
Does the Gly203Ser cardiac troponin-I mutation alter atrial/atrioventricular conduction and heart rate variability in a murine model of hypertrophic cardiomyopathy?
p-value: p=<0.001
In a murine model of hypertrophic cardiomyopathy, mice developed slowed atrial and atrioventricular conduction and depressed heart rate variability, which may indicate atrial and ventricular hypertrophy or dysfunction.
Hypothesis-generating for conduction changes in HCM; leaves open clinical relevance without human validation.
Hypertrophic cardiomyopathy (HCM) is a common heritable cardiac disorder with diverse clinical outcomes including sudden death, heart failure, and stroke. Depressed heart rate variability (HRV), a measure of cardiac autonomic regulation, has been shown to predict mortality in patients with cardiovascular disease. Cardiac autonomic remodelling in animal models of HCM are not well characterised. This study analysed Gly203Ser cardiac troponin-I transgenic (TG) male mice previously demonstrated to develop hallmarks of HCM by age 21 weeks. 33 mice aged 30 and 50 weeks underwent continuous electrocardiogram (ECG) recording for 30 min under anaesthesia. TG mice demonstrated prolonged P-wave duration (P < 0.001) and PR intervals (P < 0.001) compared to controls. Additionally, TG mice demonstrated depressed standard deviation of RR intervals (SDRR; P < 0.01), coefficient of variation of RR intervals (CVRR; P < 0.001) and standard deviation of heart rate (SDHR; P < 0.001) compared to controls. Additionally, total power was significantly reduced in TG mice (P < 0.05). No significant age-related difference in either strain was observed in ECG or HRV parameters. Mice with HCM developed slowed atrial and atrioventricular conduction and depressed HRV. These changes were conserved with increasing age. This finding may be indicative of atrial and ventricular hypertrophy or dysfunction, and perhaps an indication of worse clinical outcome in heart failure progression in HCM patients.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2015) studied Hypertrophic cardiomyopathy (n=33). Gly203Ser cardiac troponin-I transgenic mutation vs. Controls was evaluated on ECG and HRV parameters (P-wave duration, PR intervals, SDRR, CVRR, SDHR) (p=<0.001). Transgenic mice with hypertrophic cardiomyopathy demonstrated prolonged P-wave duration and PR intervals (P<0.001) and depressed heart rate variability compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: